The Pharma Data

NOVEMBER 18, 2020

These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. .”

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

APRIL 26, 2023

Gene-editing methods allow researchers to modify DNA, resulting in alterations in physical characteristics such as eye colour and susceptibility to diseases. To achieve this, scientists utilise various technologies that function similarly to scissors, precisely cutting the DNA at a particular location. References: 1. Genome.gov.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 104

Engineering Virus Therapies Immune Response 104

Drug Discovery World

JULY 31, 2023

Matt Hill , Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. The expansion of nucleic acid-based therapies One factor contributing to increased investment during this time was the success of the mRNA-based Covid-19 vaccine.

DNA 130

DNA Vaccine Therapies Production 130

Drug Discovery World

MAY 29, 2024

DNA purification “Plasmid DNA is an incredibly important part of molecular biology”, says Hummersone. This is because ultimately, when it comes to what is going to be used for the patient, it is used as a bulk commodity, as we’ve seen more recently with things like vaccines.

Therapies 273

Therapies Molecular Biology DNA Immune Response 273

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

Drug Discovery World

APRIL 15, 2023

As such, Codagenix has previously demonstrated that CodaLytic, a codon-modified influenza virus, can kickstart the cancer immunity cycle at various steps in several mouse models with differing baseline immune contextures.

Virus 130

Virus Clinical Trials Trials Therapies 130

Drug Discovery World

APRIL 12, 2023

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. Dr Paul Burton, the Chief Medical Officer of Moderna, told the Guardian: “We will have that vaccine and it will be highly effective, and it will save many hundreds of thousands, if not millions of lives.

Vaccine 130

Vaccine Immune Response RNA DNA 130

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Immune Response Disease Clinical Trials 40

Drug Discovery World

SEPTEMBER 6, 2022

Thompson says that the development of Covid-19 vaccines, which used mRNA technology, resulted in wider acceptance for cell and gene therapies. . “On On the flipside, much of biomanufacturing facilities are now focused on vaccine production which results in less capacity for other critical therapeutic areas,” Thompson adds. .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Drug Discovery World

MAY 11, 2023

Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases. In these cases, injection of the viral vector vaccines induced the production of antibodies recognising platelet factor 4 (PF4) found on patients’ platelets 1.

Production 130

Production Vaccine Immune Response Therapies 130

PLOS: DNA Science

MAY 16, 2024

Had we grown complacent in a world freed from a list of once-deadly infectious diseases, thanks largely to vaccines and other public health measures? Many of the links below are to some of the 100+ DNA Science posts that I wrote during the pandemic. Work on vaccines ensued too. COVID clearly caught us off guard.

Virus 82

Virus DNA RNA Laboratories 82

Drug Target Review

JANUARY 15, 2024

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. To be therapeutically useful, antigenic peptides must be presented in a way that allows immune responses to destroy cancer cells without causing unacceptable damage to healthy tissue.

Engineering 109

Engineering DNA Virus Medical Schools 109

Drug Discovery World

AUGUST 1, 2023

Messenger RNA (mRNA) As defined by the National Human Genome Research Institute, mRNA is a type of single-stranded RNA involved in protein synthesis, made from a DNA template during the process of transcription 4.

RNA 130

RNA Vaccine Drugs Disease 130

The Pharma Data

OCTOBER 14, 2020

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., Sergei Rudchenko, Ph.D.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Florian S, Mitchison TJ. Chang, P. &

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. The new vaccine remains stable for a time in the refrigerator. WEDNESDAY, Jan. 13 in the New England Journal of Medicine.

Vaccine 40

Vaccine Trials Immune Response Clinical Trials 40

Drug Discovery World

MAY 30, 2023

Very recent data from Moderna’s and BioNTech’s personalised vaccines in combination with ICIs in melanoma and pancreatic cancer respectively have shown dramatic improvements when given as part of a triple combination (vaccine plus ICI and chemo/radiotherapy).

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

The Pharma Data

JANUARY 21, 2021

The test valuates mitochondrial DNA levels. When mitochondrial DNA, normally found inside cells, in the mitochondria, spills into the bloodstream, it signals that a particular type of violent cell death is occurring. They measured the patients’ mitochondrial DNA levels on the first day of their hospital stays. found in the U.K.

Research 52

Research DNA Vaccine Immune Response 52

Drug Discovery World

FEBRUARY 2, 2023

The other EpicentRx platform, which complements and synergises with CyNRGY, is called AdAPT for the development of oncolytic adenovirus-based therapies that deliver transgenes or vaccine antigens to target cells and tissues.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

The Anticancer Fund

MARCH 24, 2023

Vitamin C boosts DNA demethylation in TET2 germline mutation carriers Published in Clinical Epigenetics This interesting study looked at a single family harbouring a germline mutation in the TET2 that is associated with lymphoma.

Drugs 52

Drugs DNA Trials Treatment 52

Drug Discovery World

FEBRUARY 8, 2023

This helps ensure a high concentration of loaded capsids and adequate removal of impurities, such as host cell proteins and DNA. In AAV therapeutics, empty capsids are those that are not packaged with the therapeutic DNA. A crucial part of the AAV workflow is the purification of viral vectors.

Therapies 130

Therapies Virus Packaging Production 130

The Pharma Data

DECEMBER 20, 2020

CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19. The technology used for the CureVac vaccine is similar to that utilized by Pfizer-BioNTech and Moderna. Russia’s Sputnik V COVID-19 vaccine demonstrated 91.4% Here’s a look.

Vaccine 52

Vaccine Trials Small Molecule Therapies 52

The Pharma Data

DECEMBER 27, 2020

CureVac and the University Medical Center of Mainz launched a Phase III trial of CVnCoV, their COVID-19 vaccine candidate, in healthcare workers. The study will evaluate the safety and immunogenicity of the vaccine in a two-dose schedule of 12 micrograms. platforms and the human GM-CSF cytokine. Most Read Today. Source link.

Clinical Trials 52

Clinical Trials Trials Therapies RNA 52

Codon

APRIL 9, 2023

Thousands of transcription factors — proteins that bind DNA and control gene expression — were studied in human cells. Read DNA Sequencing & Synthesis *Quantitative analysis of tRNA abundance and modifications by nanopore RNA sequencing. Read Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults.

Therapies 52

Therapies RNA Engineering Vaccine 52

Codon

MARCH 26, 2023

Link A DNA tumor virus globally reprograms host 3D genome architecture to achieve immortal growth. Link DNA storage in thermoresponsive microcapsules for repeated random multiplexed data access. Link Semi-rational evolution of a recombinant DNA polymerase for modified nucleotide incorporation efficiency. npj Vaccines.

DNA 52

DNA Engineering RNA Small Molecule 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Promising new malaria vaccine for kids approved in Ghana.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Promising new malaria vaccine for kids approved in Ghana.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 16, 2023

Skin microbes can trigger strong immune responses. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study. coli DNA using a Retro-Cascorder.

Engineering 52

Engineering DNA RNA Science 52